Skip to main content
Top

2024 | OriginalPaper | Hoofdstuk

19. Contrastmiddelen

Auteur : Jurgen Peerlings, PhD. MSc

Gepubliceerd in: Radiologie

Uitgeverij: Bohn Stafleu van Loghum

share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Samenvatting

In dit hoofdstuk komt het ontstaan en de wetenschappelijke evolutie van contrastmiddelen binnen de radiologie aan bod. Hierbij wordt de focus gelegd op contrastmiddelen die klinisch gebruikt kunnen worden voor beeldvormingstechnieken gebaseerd op röntgenstralen. Contrastmiddelen voor MRI of echografie komen niet aan bod. Na de presentatie van een overzicht van de verschillende soorten contrastmiddelen, zoals zuurstof, lucht, CO2, barium(suspensie) en jodium, en hun mogelijke toepassingen, gaan we dieper in op jodiumhoudende contrastmiddelen. We geven uitleg over de chemische eigenschappen (osmolaliteit en osmotische activiteitscoëfficiënt, osmolariteit, viscositeit, (non-)ionische verbindingen en densiteit) en hoe deze eigenschappen invloed hebben op de patiëntveiligheid, en over het klinisch gebruik van deze contrastmiddelen. Overige aandachtspunten bij het gebruik van contrastmiddel die aan bod komen zijn contrastnefropathie en de preventie ervan, het gebruik bij zwangerschap, het nut van vooraf opwarmen en de dosering.
Literatuur
1.
go back to reference Katayama H, Yamaguchi K, Kozuka T, Takashima T, Seez P, Matsuura K. Adverse reactions to ionic and nonionic contrast media. A report from the Japanese Committee on the Safety of Contrast Media. Radiology. 1990;175:621–8. Katayama H, Yamaguchi K, Kozuka T, Takashima T, Seez P, Matsuura K. Adverse reactions to ionic and nonionic contrast media. A report from the Japanese Committee on the Safety of Contrast Media. Radiology. 1990;175:621–8.
2.
go back to reference Suh YJ, Yoon SH, Hong H, et al. Acute adverse reactions to nonionic iodinated contrast media: a meta-analysis. Invest Radiol. 2019;54(9):589–99.CrossRefPubMed Suh YJ, Yoon SH, Hong H, et al. Acute adverse reactions to nonionic iodinated contrast media: a meta-analysis. Invest Radiol. 2019;54(9):589–99.CrossRefPubMed
3.
go back to reference Nijssen EC, Rennenberg RJ, Nelemans PJ, et al. Prophylactic hydration to protect renal function from intravascular iodinated contrast material in patients at high risk of contrast-induced nephropathy (AMACING): a prospective, randomised, phase 3, controlled, open-label, non-inferiority trial. Lancet. 2017;389(10076):1312–22.CrossRefPubMed Nijssen EC, Rennenberg RJ, Nelemans PJ, et al. Prophylactic hydration to protect renal function from intravascular iodinated contrast material in patients at high risk of contrast-induced nephropathy (AMACING): a prospective, randomised, phase 3, controlled, open-label, non-inferiority trial. Lancet. 2017;389(10076):1312–22.CrossRefPubMed
4.
go back to reference Nijssen EC, Nelemans PJ, Rennenberg RJ, et al. Impact on clinical practice of updated guidelines on iodinated contrast material: CINART. Eur Radiol. 2020;30:4005–13.CrossRefPubMedPubMedCentral Nijssen EC, Nelemans PJ, Rennenberg RJ, et al. Impact on clinical practice of updated guidelines on iodinated contrast material: CINART. Eur Radiol. 2020;30:4005–13.CrossRefPubMedPubMedCentral
5.
go back to reference Brouwers ACAA. Handout contrastmiddelen NVMBR. Bayer Schering Pharma; 2009. Brouwers ACAA. Handout contrastmiddelen NVMBR. Bayer Schering Pharma; 2009.
6.
go back to reference College voor zorgverzekeringen. Farmacotherapeutisch Kompas. Diemen: CVZ; 2010. College voor zorgverzekeringen. Farmacotherapeutisch Kompas. Diemen: CVZ; 2010.
7.
go back to reference Hexabrix en Telebrix, summary of product characteristics (SMPC). Guerbet. Hexabrix en Telebrix, summary of product characteristics (SMPC). Guerbet.
8.
go back to reference Iomeron, summary of product characteristics (SMPC). Bracco. Iomeron, summary of product characteristics (SMPC). Bracco.
9.
go back to reference Loembé B. Handout contrastnefropathie (Contrast Induced Nephropathy, CIN). Bayer Healthcare. Loembé B. Handout contrastnefropathie (Contrast Induced Nephropathy, CIN). Bayer Healthcare.
10.
go back to reference Rengo M, Dharampal A, Lubbers M, et al. Impact iodine concentration and iodine delivery rate on contrast-enhancement in coronary CT angiography: a randomized multicenter trial (CT-CON). Eur Radiol. 2019;29(11):6109–18.CrossRefPubMed Rengo M, Dharampal A, Lubbers M, et al. Impact iodine concentration and iodine delivery rate on contrast-enhancement in coronary CT angiography: a randomized multicenter trial (CT-CON). Eur Radiol. 2019;29(11):6109–18.CrossRefPubMed
11.
go back to reference Schering AG. 75 years of diagnostic research, shaping the future. Schering AG. 75 years of diagnostic research, shaping the future.
12.
go back to reference Schering AG. More than 75 years of diagnostic research, evolutionary steps. Schering AG. More than 75 years of diagnostic research, evolutionary steps.
13.
go back to reference Schild HH. Radiological procedures and techniques, all you will ever need to know. Schering; 1993. Schild HH. Radiological procedures and techniques, all you will ever need to know. Schering; 1993.
14.
go back to reference Schild HH, Kuhl CK, Hübner-Steiner U, et al. Adverse events after unenhanced and monomeric and dimeric contrast-enhanced CT: a prospective randomized controlled trial. Radiology. 2006;240(1):56–64.CrossRefPubMed Schild HH, Kuhl CK, Hübner-Steiner U, et al. Adverse events after unenhanced and monomeric and dimeric contrast-enhanced CT: a prospective randomized controlled trial. Radiology. 2006;240(1):56–64.CrossRefPubMed
15.
go back to reference Seeliger E, Sendeski M, Rihal CS, Persson PB. Contrast-induced kidney injury: mechanisms, risk factors, and prevention. Eur Heart J. 2012;33(16):2007–15.CrossRefPubMed Seeliger E, Sendeski M, Rihal CS, Persson PB. Contrast-induced kidney injury: mechanisms, risk factors, and prevention. Eur Heart J. 2012;33(16):2007–15.CrossRefPubMed
16.
go back to reference Siers E. Contrastmiddelen. Utrecht: Wetenschapswinkel Biologie; 1999. Siers E. Contrastmiddelen. Utrecht: Wetenschapswinkel Biologie; 1999.
17.
go back to reference Speck U. X-ray contrast media overview, use and pharmaceutical aspects. Berlin Springer-Verlag; 2018. Speck U. X-ray contrast media overview, use and pharmaceutical aspects. Berlin Springer-Verlag; 2018.
18.
go back to reference Thomsen HS, Webb JAW. Contrast media, safety issues and ESUR guidelines. 2nd ed. Berlin: Springer-Verlag; 2009.CrossRef Thomsen HS, Webb JAW. Contrast media, safety issues and ESUR guidelines. 2nd ed. Berlin: Springer-Verlag; 2009.CrossRef
19.
go back to reference Ultravist Monograaf. Bayer Schering Pharma. Ultravist Monograaf. Bayer Schering Pharma.
20.
go back to reference Ultravist, summary of product characteristics (SMPC). Bayer Schering Pharma. Ultravist, summary of product characteristics (SMPC). Bayer Schering Pharma.
21.
go back to reference Urich K. Successes and failures in the development of contrast media, from Wilhelm C. Röntgen to the present. Berlin: Blackwell Wissenschaft-Verlag; 1995. Urich K. Successes and failures in the development of contrast media, from Wilhelm C. Röntgen to the present. Berlin: Blackwell Wissenschaft-Verlag; 1995.
22.
go back to reference Visipaque en Omnipaque, summary of product characteristics (SMPC). GE Healthcare. Visipaque en Omnipaque, summary of product characteristics (SMPC). GE Healthcare.
Metagegevens
Titel
Contrastmiddelen
Auteur
Jurgen Peerlings, PhD. MSc
Copyright
2024
Uitgeverij
Bohn Stafleu van Loghum
DOI
https://doi.org/10.1007/978-90-368-2913-7_19